The present invention relates to antibodies and antigen-binding portions thereof that specifically bind to CD40, preferably human CD40, and that function as CD40 agonists. The invention also relates to human anti-CD40 antibodies and antigen-binding portions thereof. The invention also relates to antibodies that are chimeric, bispecific, derivatized, single chain antibodies or portions of fusion proteins. The invention also relates to isolated heavy and light chain immunoglobulins derived from human anti-CD40 antibodies and nucleic acid molecules encoding such immunoglobulins. The present invention also relates to methods of making human anti-CD40 antibodies, compositions comprising these antibodies and methods of using the antibodies and compositions for diagnosis and treatment. The invention also provides gene therapy methods using nucleic acid molecules encoding the heavy and/or light immunoglobulin molecules that comprise the human anti-CD40 antibodies. The invention also relates to transgenic animals comprising nucleic acid molecules of the present invention.Monoklonsko antitelo ili njegov deo koji vezuje antigen koji se specifično vezuje za humani CD40 i aktivira ga, gde se epitop, koji prepoznaje navedeno antitelo ili njegov deo, ne preklapa sa mestom vezivanja za CD40 ligand, gde navedeno antitelo ili njegov deo inhibira rast tumora in vivo i gde navedeno antitelo sadrži težak lanac i lak lanac, gde:(a) su aminokiselinske sekvence CDR1, CDR2 i CDR3 navedenog teškog lanca one iz varijabilnog domena teškog lanca odabranog iz grupe koju čine:i) varijabilni domen teškog lanca 21.4.1 (ATCC depozitni br. PTA-3605)；ii) varijabilni domen teškog lanca koji sadrži aminokiselinsku sekvencu SEQ ID NO: 42 iiii) varijabilni domen teškog lanca koji kodira nukleotidna sekvenca SEQ ID NO: 41 i(b) su aminokiselinske sekvence CDR1, CDR2 i CDR3 navedenog lakog lancaone iz varijabilnog domena lakog lanca odabranog iz grupe koju čine:i) varijabilni domen lakog lanca 21.4.1 (ATCC d
